WT1 protein-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Drug Profile

WT1 protein-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Alternative Names: ATA 520; WT1 peptide-specific T-cells - Atara/MSKCC; WT1-CTL - Atara/MSKCC; WT1-sensitised T cells - Atara/MSKCC; WT1-targeted T cells - Atara/MSKCC

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Atara Biotherapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Leukaemia; Multiple myeloma

Most Recent Events

  • 23 Feb 2018 WT1 protein-specific T-cell therapy is still at phase I development stage for Leukaemia and Multiple myeloma in USA (IV) (Atara Biotherapeutics pipeline, February 2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Multiple-myeloma(Refractory metastatic disease) in USA (IV, Infusion)
  • 15 Mar 2017 Atara Biotherapeutics plans a phase I/II clinical trial in patients with Hematologic malignancies in 2018 (Atara Biotherapeutics Form 10-K, December 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top